DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for breast carcinoma in situ — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBreast carcinoma in situ maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for breast carcinoma in situ is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
BRCA2 DNA repair associated (BRCA2) — BRCA2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet atpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8PBC · 2.61 Å · ligand ADENOSINE-5'-TRIPHOSPHATE (ATP). Experimental structure, not a prediction.
What the evidence adds up to
In situ carcinomas of the breast account for 15% to 30% of newly diagnosed breast cancer cases. Management remains controversial. For ductal carcinoma in situ, five randomised trials have shown that adding radiation after lumpectomy lowers the risk of local recurrence and invasive local recurrence in the ipsilateral breast by approximately 50%. Two randomised trials have shown that adding tamoxifen reduces the risk of all breast cancer events (ipsilateral plus contralateral) by approximately 30–40%. No survival benefit has been shown for adding either radiation or tamoxifen. For lobular carcinoma in situ, hormonal treatment has been shown to reduce subsequent risk, but the abstract gives no specific numbers.
Standard approaches to risk stratification use clinical and pathologic characteristics such as patient age, lesion size, and grade. Lobular carcinoma in situ has a subsequent risk that is more frequently bilateral than ductal carcinoma in situ. Most patients are asymptomatic at initial presentation, and standard treatments carry the risk of side effects. It can be difficult for an individual patient to find the most appropriate balance between the risks and benefits of adding treatment.
More recent efforts have focused on the value of molecular markers to individualise risk profiling. To be clinically useful, molecular profiling should demonstrate value beyond that seen using standard clinical and pathologic factors. Current efforts have focused on using molecular profiling as a prognostic factor; future efforts will evaluate it as a predictive factor. The 2013 article notes that in the molecular progression from normal tissue to invasion, in situ carcinoma is a late-occurring step associated with an increased risk of subsequent invasive carcinoma.
What is still missing is a validated molecular profiling tool that can reliably predict which patients will benefit from additional treatment and which can safely avoid it. No such predictive test is yet in routine clinical use for in situ disease. The randomised trials that showed risk reduction did not demonstrate a survival benefit, leaving the question of overtreatment unresolved. Prospective trials that incorporate molecular stratification and are powered for survival endpoints remain to be funded and conducted.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PubMed · 2016 · 1 citations
[Chinese expert consensus on the diagnosis and treatment of breast carcinoma in situ].
AbstractIn situ carcinomas of the breast constitute 15% to 30% of all newly diagnosed breast cancer cases. Although the concept of carcinoma in situ has been proposed for a long time, there is still a great controversy regarding the screening, diagnosis and treatment. This article attempts to reach some consensus on the management of ductal carcinoma in situ and lobular carcinoma in situ and provide references for clinicians in the following aspects: definition and classification, natural history and prognosis, diagnosis, local and systemic treatment for primary carcinoma in situ, recurrence risk and treatment approaches for recurrent cancers.
Abstract ES1-1: Molecular Profiling for In Situ Carcinoma of the Breast
AbstractAbstract The management of in situ carcinoma of the breast represents a clinical dilemma. Such a non-invasive lesion places the patient at risk for subsequent development of an invasive lesion, and various treatments have been shown to reduce this risk. However, most patients are asymptomatic at initial presentation, and standard treatments are associated with the risk of side effects. It can be difficult for the individual patient to find the most appropriate balance between the risks and benefits of adding treatment. Although many patients elect for all treatments to minimize risk of progression regardless of potential side effects, other patients elect against treatment, often because of the potential risk of associated side effects. Standard approaches to managing the patient with in situ disease have employed various clinical and pathologic characteristics to assess and stratify risk. Models for determining risk have used a number of clinical and pathologic characteristics, including patient age, lesion size, and grade. Ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS) have different risk profiles. For example, LCIS is well known to have subsequent risk that is more frequently bilateral than DCIS. Prospective randomized clinical trials for DCIS have demonstrated a substantial reduction in the risk of recurrence associated with adding radiation treatment and tamoxifen after lumpectomy. Five randomized DCIS trials have shown that adding radiation treatment after lumpectomy lowers the risk of local recurrence and invasive local recurrence in the ipsilateral breast by approximately 50%. Two randomized DCIS trials have demonstrated that adding tamoxifen reduces the risk of all breast cancer events (combined ipsilateral plus contralateral) by approximately 30–40%. No survival benefit has been shown for adding either radiation or tamoxifen. For LCIS, hormonal treatment has been shown to reduce subsequent risk. More recent efforts have focused on the value of molecular markers to individualize and tailor risk profiling for the individual patient. Using such molecular risk profiling, adding treatment can be selected for higher risk patients, and omitting treatment can be chosen for lower risk patients. To be clinically useful, molecular profiling should demonstrate value beyond that seen using standard clinical and pathologic factors. While current efforts have focused on using molecular profiling as a prognostic factor, future efforts will evaluate molecular profiling as a predictive factor. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr ES1-1.
AbstractMolecular profiling is used in three stages of breast cancer development: cacinoma in situ, primary, and metastatic. The treatment of in situ carcinoma of the breast is controversial. In the molecular progression from normal tissue to invasion, in situ carcinoma is a late-occurring step associated with an increased risk of the subsequent development of invasive carcinoma [Bombonati A, Sgroi DC. J Pathol 2011]. This article discusses data on molecular profiling of in situ carcinoma of the breast, an overview of molecular profiling of breast cancer, and the current use of genomic and molecular tests in routine practice and clinical research in metastatic breast cancer.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
